CYP2D6 polymorphism is associated with variability in drug response, endogenous metabolism (that is, serotonin), personality, neurocognition and psychopathology. The relationship between CYP2D6 genetic polymorphism and the risk of eating disorders (ED) was analyzed in 267 patients with ED and in 285 controls. A difference in the CYP2D6 active allele distribution was found between these groups. Women carrying more than two active genes (ultrarapid metabolizers) (7.5 vs 4.6%) or two (67 vs 58.9%) active genes were more frequent among patients with ED, whereas those with one (20.6 vs 30.2%) or zero active genes (4.9 vs 6.3%) were more frequent among controls (Po0.05). Although further research is needed, present findings suggest an association between CYP2D6 and ED. CYP2D6 allele distribution in patients with ED seems related to increased enzyme activity.
Introduction
CYP2D6 genetic polymorphism is related to variability of the enzyme hydroxylation capacity. Subjects carrying zero CYP2D6 active genes are classified as poor metabolizers (PMs). The rest are extensive metabolizers (EMs), including a group of ultrarapid metabolizers (UMs). UMs carry more than two active CYP2D6 alleles and have a hydroxylation capacity that is more than 100 times higher than that of PMs. The frequency of PMs and UMs in Spain is 7-10% and 4.9%, respectively. 1 CYP2D6 is involved in the metabolism of drugs used in the treatment of eating disorders (EDs), such as the antidepressant fluoxetine. 2, 3 In clinical practice, women with ED are also likely to take other drugs metabolized by CYP2D6 (paroxetine, fluvoxamine, venlafaxine, citalopram) for treating comorbid or lifetime psychiatric disorders such as major depression, obsessive-compulsive disorder and so on. CYP2D6 is also involved in endogenous metabolism, 4 in particular in regeneration of serotonin from 5-methoxytryptamine. 5 Moreover, CYP2D6 has been related to differences in serotonin in platelets. 6 As the serotonin and dopamine systems functionally interact in the human brain, with feedback circuitries between the two pathways, CYP2D6 may also have a role in mental illness through modulation of dopamine tone through serotonin. 7 Therefore, PMs relative to EMs may have different baseline serotonin concentrations in brain regions in which CYP2D6 is expressed, such as the cortex or hippocampus, among others. 5, 8 In keeping with that observation, we previously described the involvement of genetic variability in CYP2D6 in psychological functioning in different cultural environments 9-10 and in neurocognition. 11 Moreover, we have shown that PMs appear to present lower psychopathology compared with EMs. [11] [12] Consistently, UMs appear more frequent among individuals who commit suicide, 13 or who present persistent mood disorder, 14 as well as among women with postpartum depression. 15 In addition, altered serotonin neurotransmission and associated comorbid affective disorders are frequently described in ED. [16] [17] [18] Thus, in light of these observations, we aimed to analyze the relationship between CYP2D6 genetic polymorphism and susceptibility to ED.
Materials and methods
The clinical sample consisted of 267 Caucasian patients with ED consecutively recruited from Bellvitge University Hospital (Barcelona, Spain). All subjects fulfilled the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, criteria for ED. The control group was composed of 285 women: 101 students and staff from Extremadura University Hospital and Medical School, who were described in detail previously, 10 and 184 women attending a primary healthcare center in Badajoz with no history of ED (Diagnostic and Statistical Manual of Mental Disorders, 4th edition) and psychotropic treatment according to clinical and psychiatric evaluation by experienced clinicians. All participants (age range: 18-55 years old) were female, of European ancestry and living in Spain. The study was performed according to Helsinki Declaration principles. All participants gave written informed consent and corresponding ethical approval was obtained from the institutions involved in the study.
CYP2D6 was analyzed according to the methodology previously described. 1 Differences in the distribution of alleles between patients and controls were measured using linear-by-linear association w 2 -test and 95% confidence interval.
Results
The genotypes were in Hardy-Weinberg equilibrium. A difference in the CYP2D6 active alleles distribution was found between patients with ED and controls (Po0.05): Whereas women carrying two or more than two active genes were more frequent among patients with ED, those with one or zero active genes were more frequent in the control group (Table 1) .
Discussion
Present results suggest an association between CYP2D6 gene copy number distribution and ED. Patients with ED seem to have an atypical allele distribution characterized by an increased frequency in individuals with two or more active genes and a decreased frequency in individuals with one or zero active genes. This pattern suggests that patients with ED could have an increased CYP2D6 activity, which may be relevant while using CYP2D6 substrates for treatment. However, further research is needed to overcome the limitations inherent in the present design, including the control for potential biases derived from recruiting individuals who volunteer for this type of study. 12 Present findings seem to be in agreement with previous results showing that UMs are more frequent among suicide cases, 13 persistent mood-disordered patients 14 and among women with symptoms of depression, 15 which usually overlap with ED. [16] [17] [18] In addition, we have previously reported that PMs are less frequent among schizophrenic patients than among healthy subjects (2.3 vs 8.5%, respectively), 19 which would be in accordance with lower scores on a measure of risk to psychopathology or general distress also found among PM healthy volunteers. 11 Moreover, PMs seem to perform better on a cognitive task that assesses sustained attention, a trait characteristically impaired in patients with schizophrenia, bipolar depression and attention and deficit hyperactive disorder.
11 All these data support the role of CYP2D6 in endogenous metabolism and its potential implication for psychopathology.
11-12
Curiously, fluoxetine-recommended doses for the treatment of binge eating and purging in ED are higher (60 mg per day) than clinically recommended dosages for other disorders. 3, 20 Further research is required to determine whether the use of higher doses of CYP2D6 substrates or normal doses under polytherapy in patients with ED might be related to a higher frequency of individuals with high CYP2D6 metabolic capacity.
Present findings and preexisting data support the hypothesis that CYP2D6 gene copy number may alter brain concentrations of serotonin and thus the risk of developing an ED.
